Drug ID: 2d00000056
Drug Name: Brentuximab Vedotin
Generic Names: Adcetris
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose is 1.8 mg/kg, over 30 minutes infusion every 3 weeks.
Recommended In: This medication is a monoclonal antibody, prescribed for certain types of lymphoma (Hodgkin lymphoma, systemic anaplastic large cell lymphoma [sALCL]). It works by killing cancer cells.
Directions For Use: It comes as a solution for injection, to be administered by a healthcare provider into the vein.
Storage: Store vial at 2-8°C.
Dosage Forms: Intravenous Injection
Side Effects: Most Common - Decrease in white blood cells, anemia, peripheral sensory neuropathy, fatigue, nausea, fever, rash, diarrhea and pain.
Blood - Swelling of lymph nodes and decrease in platelet counts.
Central Nervous system - Headache, sleeplessness, anxiety and dizziness.
General - Chills and swelling in the extremities.
Infections - Upper respiratory tract infection.
Gastrointestinal - Abdominal pain, vomiting and constipation.
Skin - Itching, hair loss, night sweats and dry skin.
Respiratory - Cough, difficulty in breathing and throat pain.
Musculoskeletal - Joint pain, muscle pain, back pain and muscle spasms.
Metabolic - Decreased appetite and weight.
In Case of Overdose: There is no known antidote for overdosage of Brentuximab Vedotin. In case of overdosage, the patient should be closely monitored for adverse reactions, particularly neutropenia, and supportive treatment should be administered.
Avoid If: Caution should be exercised in patients with history of nerve problem, any allergy, who are taking other medications, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery while taking this medication.
It may decrease platelet counts; avoid injury or bruising.
Avoid contact with people who have infections that may spread to others.
Patient may develop with increased risk of tumor lysis syndrome (TLS), and viral brain infection (fatal conditions) with the following symptoms: irregular heartbeat, fainting, decreased urination, muscle weakness or cramps, dizziness, difficulty in talking, poor eyesight, nausea, vomiting, diarrhea, or loss of appetite; if it is so consult with your healthcare provider.
Drug Interaction: Some products that may interact with this drug include: bleomycin, other drugs that weaken the immune system/increase the risk of infection (such as natalizumab, rituximab).
Other medications can affect the removal of brentuximab from your body, which may affect how brentuximab works. One example is rifampin, among others.